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Background & Aims: Long chain omega-3 polyunsaturated fatty acids (n-3 PUFA), such as docosahexa-
enoic acid (DHA) are widely considered beneﬁcial for infant health and development. The aim of this
meta-analysis was to summarize the evidence related to the clinical outcomes of long chain n-3 PUFA
supplementation maternally and in fortiﬁed formula/taken directly. Additionally, we investigate if the
addition of arachidonic acid (AA) alters the effects caused by n-3 PUFA supplements.
Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE (1974 to
June 2015) CINAHL (1990 to June 2015), PubMed (1966e2015), Web of Science (1864e2015), MEDLINE
(1974 to June 2015), and hand searches for randomized and semi-randomized controlled trials on term
infants evaluating the effects of long chain n-3 PUFA supplementation taken maternally and in milk
based formula or directly.
Results: We identiﬁed 39 formula and 39 breastmilk studies on the clinical outcomes of long chain n-3
PUFA supplementation, with or without AA, on infant immunity and development. Of these studies, 32
formula and 37 breastmilk studies were deemed appropriate resulting in a total of 2443 formula fed
infants and 4553 breastfed infants exposed to n-3 PUFA supplementation. This meta-analysis shows that
n-3 PUFA supplementation in infants delivered either maternally or in formula/directly, does not
improve visual acuity, language development, or cognition. However, some aspects of growth, motor
development, behavior and cardiovascular health are differentially altered in the summary effects of
certain studies with the more desired effect occurring often in breastfed infants compared to formula fed
infants. Moreover, this meta-analysis shows that n-3 PUFA supplements affects infant immune devel-
opment and reduces pro-inﬂammatory responses in the supplemented breastfed and fortiﬁed formula
fed/directly supplemented infants.
Conclusion: Overall, the evidence does not support the continued supplementation of infant formula
with long chain n-3 PUFA considering the negative impact on the developing immune responses.
Crown Copyright © 2016 Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
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Infant development during the last trimester of pregnancy and
the ﬁrst year of life is considered critical for many clinical outcomes
like behavior, cognition as well as immunity. During this time of
gestation and infancy, there is a large demand for n-3 poly-
unsaturated fatty acids (n-3 PUFA), like docosahexaenoic acid
(DHA), as well as the n-6 PUFA arachidonic acid (AA) [1]. Several
scientiﬁc and clinical studies show a deﬁciency in n-3 PUFA nega-
tively impacts physiological outcomes in infants including visual
development [2], behavior [3], and cognition [4]. Indeed, numerous
studies have found positive correlations between n-3 PUFA con-
sumption and cognition or visual outcomes, although randomized
controlled clinical trials are not conclusive [5]. In addition, several
studies have linked ﬁsh consumption, rich in n-3 PUFA, with infant
anthropometric measures [6e8] although the long term biological
effect of this is unknown. DHA has also been proposed to exert a
suppressive effect in cardiovascular [9] and other chronic
inﬂammatory-related diseases [10] suggesting that DHAmodulates
immunity. Accordingly, n-3 PUFA intake, in particular DHA, has
been expected to provide beneﬁcial effects on infant health and
development.
Dietary lipid intake during the pre and post-natal period alters
the biochemistry and physiology of the developing infant. Lipids
are supplied to infants through placental transfer and breastmilk
[1] and amother's diet inﬂuences breastmilk lipid composition [11].
Indeed, DHA in breastmilk is lower in mothers who do not sup-
plement [12]. Similarly, term infants fed standard formula, notfortiﬁed with n-3 PUFAs, have lower DHA and AA in their eryth-
rocytes [13] and lower n-3 PUFAs in their cerebral cortex than
breastfed infants. Yet, previous meta-analyses on breastfed infants
supplemented with n-3 PUFA [14] and fortiﬁed formula [15]
conclude that n-3 PUFA supplementation cannot be supported or
refuted in infants. Still, the American Pregnancy Association rec-
ommends 300 mg of DHA daily supplements to pregnant mothers
since DHA is deemed essential for neurological and visual devel-
opment in infants [16] with similar claims made by several infant
formula manufacturers.
The aim of this study, was to update previous meta-analyses
thoroughly evaluating all clinical trials assessing the effects of n-3
PUFA supplementation, taken maternally or through formula/
directly, on infant health and development. Our selection criteria
identiﬁed 32 infant formula/directly supplemented and 37 breast-
milk studies providing data on 2443 infants on n-3 PUFA supple-
mented formula/direct and 4553 infants feeding from mothers
supplemented with n-3 PUFA. This meta-analysis shows that n-3
PUFA supplementation in infants, delivered either maternally or in
formula/directly, does not improve visual acuity, language devel-
opment, or cognition. However, some aspects of growth, motor
development, behavior and cardiovascular health are differentially
altered in the summary effects with the more desired effect
occurring often in breastfed infants compared to formula fed in-
fants. Moreover, this meta-analysis suggests that n-3 PUFA sup-
plementation may affect infant immune development reducing
normal pro-inﬂammatory responses in both breastfed and formula
fed infants. Overall, the evidence does not support the continued
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are required to understand the effects of maternal n-3 PUFA sup-
plementation on infant immunity.
2. Materials and methods
2.1. Inclusion and exclusion criteria
The inclusion and exclusion criteria were determined prior to
our literature search. Inclusion criteria for the breastfeeding group
included trials that examined infants born to breastfeeding women
receiving n-3 PUFA supplementation during gestation and/or dur-
ing lactationwith breastmilk as the infant's primary dietary source.
Mothers must have started supplementing either during gestation
or within 2 weeks of lactation. In the formula feeding group we
included infants that were fed milk based n-3 PUFA supplemented
formula ± AA or given an n-3 PUFA supplement directly within 2
weeks of birth. In both groups, infants were born at term or 37
weeks gestation. We excluded studies that were: not clinical trials,
did not report on clinical infant immunity or development, the
infants were born pre-mature, or the reports were abstracts or
unpublished.
2.2. Literature search strategy
Without language restrictions, we searched according to the
standard search strategy of the Cochrane Neonatal Review Group
including electronic searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), EMBASE (1974 to June 2015), CINAHL
via EBSCO (1990 to June 2015), MEDLINE (1974 to June 2015), Web
of Science (1864e2015), PubMed (1966e2015), as well as reference
lists of published narrative and systematic reviews using the search
terms listed in the supplementary materials (Table S23).
2.3. Study selection
Randomized and semi-randomized controlled trials evaluating
the effects of maternal long chain n-3 PUFA supplementation dur-
ing gestation and/or lactation or the effects of long chain n-3 PUFA
supplementation orally or to infant formula fulﬁlled the selection
criteria. A trial was deﬁned as semi-random if the method used to
allocate study mothers to a n-3 PUFA group was either not statis-
tically random or was not clearly stated. The titles and abstracts of
the identiﬁed studies were screened independently by two authors.
The full articles of relevant trials were assessed to determine their
eligibility for inclusion in this meta-analysis with any disagreement
resolved by a discussion between all authors. We included one
study where the control groups did not supplement with any pla-
cebo on religious grounds.
2.4. Types of interventions
We evaluated long chain n-3 PUFA supplementation taken
maternally during gestation, gestation and lactation, or lactation
only compared to a control group (placebo or no supplementation),
and long chain n-3 PUFA supplemented milk based formula or
capsule compared to a non-supplemented control. The source of n-
3 PUFA supplements were from fungal oils, ﬁsh oils, single-cell
sources, or egg triglycerides.
2.5. Subgroups
Studies were sub-grouped according to the outcomes in each
paper. Prior to our literature search we determined that wewanted
to see if the addition of AA had any effect on the DHA supplements,thus, DHAþ AA supplements were analyzed separately from an n-3
PUFA supplement alone.
2.6. Effect direction
Tables S1-S22C indicates where a bigger value is considered
better (BB) or a smaller value is better (SB) for all the following
outcome measures. This allows us to assign a positive score to the
treatment group when they have the desirable outcome.
3. Outcome measures
The particular outcome as speciﬁed in the original trials is re-
ported. Our primary outcomes assessed included: visual acuity,
cardiovascular health, immunity, growth and neurodevelopment
(language, cognition, and motor development). Growth related to
head circumference, height, weight and additional growth pa-
rameters such as body mass index (BMI) and fat distribution.
3.1. Visual acuity
During Teller acuity card tests (TAC), infants are presented with
cards of increasing special frequencies; the highest special fre-
quency distinguished by the infant determines visual acuity. Visual
evoked potentials (VEP) examine corneal reﬂection. Flash VEPs give
overall information on visual pathways; the responses include
mean peak latencies of the major negative (N) and positive (P)
components in the response waveform, which are numbered in a
timed sequence. In transient (T) VEPs, the brain's response returns
to the resting state before the next stimulus, and as a result pro-
duces a waveform with distinct VEP components [17]. In contrast,
steady state (SS) VEPs do not return to resting state between
stimuli. Binocular visual acuity is assessed using the sweep VEP
method, which measures the amplitude of the electrical response
in the occipital cortex of an infant as visual stimuli, such as bars or
square wave gratings, are rapidly presented. In contrast, early
treatment diabetic retinopathy study (ETDRS)/Bailey-Lovie (BL)
charts and the HOTV test, screen for monocular visual acuity.
Electroretinography (ERG) tests for any abnormalities in the retina
and the Beery visual motor index (BVMI) tests for visual spatial
skills. Finally, the developmental test of visual motor integration
(DVMI) is designed to test for deﬁcits in visual perception.
3.2. Motor development
Motor development included psychomotor, motor develop-
ment, and general movements. These were assessed using the
following methods: gross motor skills were assessed with the leg
coordination subtest of the McCarthy scales of children's ability
(MSCA) and the handmovement subset of the Kaufman assessment
battery for children (K-ABC). The MCSA is a standardized test with
predictive validity comprising of a verbal, a perceptional-
performance, quantitative, memory and motor scales; the motor
scales were included in the motor development category. Fine
motor skills were assessedwith the Purdue pegboard test (PPT) and
the motor component of the developmental test of visual motor
integration (DVMI). The PPT test examines both gross (arms, hands
and ﬁngers) and ﬁne (“ﬁngerprint” dexterity) motor skills by
requiring the participant to place pins in the holes of a pegboard as
quickly as possible. In addition, measurements of early and late
gestures, general movement (GM), and neonatal neurological
classiﬁcation (NNC) were used. The Bayley scale of infant devel-
opment (BSID) is a standardized test in which scores from devel-
opmental play tasks are converted to scale and composite scores,
which are used to compare the participant's performance to the
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motor components were used. The Gesell gross motor develop-
mental quotient examines various gross and ﬁne motor functions
such as lying, rolling, and sitting and gives an overall score. The
Knobloch, Passamanik and Sherrards test (KPST) is comprised of
ﬁve scales: adaptive, gross motor, ﬁne motor language and
personal-social skills; the ﬁne and gross motor scores were used to
determine motor development. Similar to the KPST, the Grifﬁths
mental development scales (GMDS) uses a standardized kit to test
for gross motor skills, personal-social skills, language skills, hand
eye co-ordination (ﬁne motor skills), performance, and practical
reasoning; outcomes from the gross and ﬁne motor skills were
likewise included in the assessment of motor development. The
Brunet-Lezine psychomotor developmental quotient (DQ) is a test
for psychomotor development in early childhood, which examines
posture control, hand-eye coordination, language, and personal/
social relations [18].
3.3. Language development
The Peabody picture vocabulary test (PPVT) provides a quick
estimate of verbal skills where an examiner says a word and the
individual being tested is asked to point to a picture (out of 4) that
corresponds to that word. The clinical linguistic and auditory
milestone scale (CLAMS) tests linguistic and auditory milestones in
infants [19]. The child development inventory, (CDI) is a question-
naire that measures child development in social, self-help, gross
motor, ﬁne motor, expressive language, language comprehension,
letters and numbers; we included the expressive language and
language comprehension in this category. The MacArther
communicative development inventory (MCDI) is based on the idea
that language and gestures are tightly coupled and early and late
gestures can be used to predict future language skills [20].
3.4. Behavior
A strengths anddifﬁculties questionnaire (SDQ) tests behavior by
askingquestionson25differentpositive andnegative attributes. The
infant behavior questionnaires (IBQ) tests six different domains of
infant temperament including: smiling and laughing, activity level,
the ability to be soothed, fear, distress to limitations, and duration of
orienting. The Bracken basic concept scale-revised (BBCS-R) evalu-
ates basic concepts essential for academic success. The child
behavior checklist (CBCL) tests emotional and behavioral problems.
3.5. Cognition
Cognitive and neurodevelopment outcomes were measured
using the following tests: the mental composite portions of the K-
ABC, the BSID: mental development index (MDI), the GMDS, the
information and block design subtests of theWechsler primary and
preschool scale of intelligence-revised (WPPSI-R), the Fagan test,
the Leiter international performance scale, the clinical adaptive test
(CAT), the Stroop test, the Woodcock Johnson (WJ) test of cognitive
abnormalities, the Stanford-Binet IQ test, the matching familiar
ﬁgures test (MFFT), the cognitive portion of the NNC, and a number
of studies used a 2 or 3 step-means end problem solving test. The
Fagan test is founded on the idea that there is a link between
preferences for visual novelty and future intelligence; infants will
look longer at a new target than one that they have previously seen.
The Leiter test is an intelligence test which looks at reasoning,
visualization, memory and attention, while the CAT tests for
problem solving abilities. The Stroop test examines reaction time to
say “sun” or “moon” when they see a picture of a sun and moon,
respectively, as well as the reaction time to say the opposite image(say “moon” when an image of the sun is shown). The WJ test is an
intelligence test consisting of 10 standard battery and 10 extended
battery tests ranging in abilities such as ﬂuid reasoning, processing
speed, and short term memory. The Stanford-Binet IQ is used to
detect intellectual deﬁciencies using both verbal and nonverbal
subtests. The matching familiar ﬁgures test is used to test measures
of the reﬂection-impulsivity dimension where a child is asked to
identify a drawing from six possible variants which is identical to
the standard drawing as quickly as possible. The two or three step-
means end problem solving test involves a support step where
infants have to pull an object within reach, and search step where
infants have to uncover the object that is usually under a blanket.
3.6. Growth
Weight, length, head circumference and other additional
growth measures were reported on. Growth Z-scores, which
convert raw scores into standardized scores relative to a population
mean, were also reported. The effect direction in the weight and
additional growth parameters have been segregated by age.Weight
and growth parameters in an infant are considered beneﬁcial be-
tween birth and two years of age. However, as the toddler ages
there is a period of adiposity rebound where it is difﬁcult to deﬁne
the desired effect direction and thus we ran both scenarios (where
weight and additional growth parameters were considered bene-
ﬁcial and where they were considered detrimental) between the
ages of 2 and 5. We considered increased weight and additional
growth parameters to be detrimental over the age of 5.
3.7. Cardiovascular health
Pulse wave velocity (PWV), the mean arterial (MAP), systolic
(SBP) and diastolic (DSP) blood pressures, and heart rate (HR) were
taken according to the oscillometric principle with an automatic
device during cuff inﬂation, and using non-invasive optical
methods. HR variability outcomes included: the mean of all normal
intervals during recording (RR), the mean of standard deviations
(SD) of all RR intervals in 5 min segments (SDNNi), the SD of RR
intervals measured in successive 5 min intervals (SDNN), the per-
centage of differences between adjacent RR intervals 50 ms
(pNN50), and the square root of the mean of the sum of the squares
of the differences between adjacent intervals (RMSSD), were
measured using electrocardiograms and illustrate regulation of the
heart by the autonomic nervous system. A decreased HR variability,
particularly the SDNNi, is a predictor of cardiovascular death and
sudden cardiac death [21].
3.8. Immunity
Immune outcomes were assessed through clinical and parental
observations, biochemical measurements of blood for immune cells
and cytokines, and skin prick tests (SPT) in which sensitization to
various allergens were measured. Ovalbumin stimulation is used to
quantify immune responses. The SPT, measures the presence of IgE
antibodies to allergens indicative of allergies. SCORing Atopic
Dermatitis (SCORAD) is a clinical tool used to assess the extent and
severity of eczema. For immune outcomes, we considered any pro-
inﬂammatory effects to be beneﬁcial since normal priming of the
immune system occurs during infancy.
3.9. Data quality
The methodological quality of the trials was assessed indepen-
dently by two reviewers following the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions [22],
Fig. 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
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supplementary materials (Fig. S1). Bias was ranked according to
sequence generation, allocation concealment, blinding, outcome
data, selective reporting, as well as other sources of bias such as
study design. When reporting bias was suspected, we attempted to
contact the study authors for missing outcome data. Where this
was not possible, the missing data was thought as serious bias. Any
disagreement was resolved by a discussion between all authors.We
did not use rank correlation tests or funnel plots to assess publi-
cation bias because these analyses are invalidated by the underly-
ing heterogeneity among effect sizes [23].
3.10. Data analysis
A ﬁxed-effect model is usedwhen therewas only one true effect.
While many of our studies look at similar interventions, the impact
of the intervention will vary between studies due to differences in
location, dosage, length of follow-up and so forth. Therefore, a
random-effect model was used to incorporate heterogeneity into
the meta-analysis [24].
3.11. Assessment of heterogeneity
When using a random effects model heterogeneity is expected
and we ran a variance of components test to ensure inappropriate
pooling had not occurred. Cochran's Q is a test of signiﬁcance
derived from weighted squared deviations that is greatly depen-
dent of the number of studies analyzed (Borenstein). I2 is simply a
ratio derived from Q. Thus when numerous effects are random we
can expect higher values of heterogeneity. Heterogeneity measures
are presented in Table S24.
3.12. Continuous data
For continuous data, we measured the standardized mean dif-
ference (SMD) using an inverse variance method at a 95% conﬁ-
dence interval.
3.13. Dichotomous data
The dichotomous data event counts were measured using an
odds ratio effect measure at a 95% conﬁdence interval.
3.14. Data synthesis
Meta-analysis was conducted through the use of the Compre-
hensive Meta-Analysis V3 program using each study as our unit ofanalysis for our deﬁned outcomes. Prior to inputting our data, any
standard errors were converted to standard deviation using the
formula SD ¼ SE* ﬃﬃﬃnp , where SD is the standard deviation, SE is the
standard error of the mean, and n is the number of participants.
When data was separated into boys and girls, a total value was
























Where nboys and ngirls are the number of boys and girls in a study
population, xboys and xgirls is the sample mean of the boys and girls,
and x is the overall sample mean. Although in some cases there
were differences observed between boys and girls, we argue that
formula companies do not provide “boys” vs. “girls” formula, and
women start supplementing with ﬁsh oil during gestation, before
they know the gender of their baby. Thus, we chose to pool the boys
and girls together. Likewise, prior to our analysis, we pooled the
variance and calculated an overall mean of a DHA category and
standard deviation for each study that tested numerous concen-
trations of DHA [25e28]. Finally, all studies derived from a larger
trial (for example the DOMInO trials) or longitudinal studies were
pooled to decrease the risk of a type 1 error.
4. Results
4.1. Studies included in the meta-analysis
We identiﬁed 39 infant formula and 39 breastmilk publications
evaluating the effects of n-3 PUFA supplementation on infant
development which ﬁt our inclusion criteria (Fig. 2.) Out of these
studies, 6 were not included in the analysis because the data was
presented in a way that could not be analyzed (in ﬁgures with no
written values, as medians and percentiles/ranges, or with conﬁ-
dence intervals instead of SD or SE) and we were unable to obtain
the raw data [29e35]. One study was excluded because reported
exclusively on the mother [36]. One study was excluded because it
did not report on clinical outcomes [37]. One study was excluded
because it did not have a randomized or blinded process [38]. This
resulted in a total of 32 infant formula [26e28,30,31,34,39e64] and
37 breastmilk publications [25,65e100] evaluating 2443 infants on
n-3 PUFA enriched formula and 4553 infants that were fed from
Fig. 2. PRISMA ﬂow diagram of included and excluded studies.
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and/or lactation. All the trials included used a randomized or semi-
randomized clinical trial design from both high and low-income
countries (Table S25) with the experimental interventions sum-
marized (Table S26) and a reference list of pooled studies
(Table S27).
4.2. Clinical effects of n-3 PUFA supplementation
4.2.1. Visual acuity
The visual acuity of infants was not affected by n-3 PUFA sup-
plementation in either breastfed (Fig. 3; SMD 0.011, 95% CI -0.106 to
0.128; seven trials) or formula fed/directly supplemented infants
(Fig. 4A; SMD -0.041, 95% CI -0.498 to 0.416; four trials. Fig. 4B; SMD
0.173, 95% CI -0.308 to 0.654; three trials). In contrast to the hy-
pothesis that n-3 PUFA would improve visual acuity, in both
breastfed and formula fed infants we predominantly see insigniﬁ-
cant results and those that are signiﬁcant are inconsistently ﬂuc-
tuating with age (individual data not shown). In the infants born to
mothers supplementing with n-3 PUFA, the VEP amplitude at 4 and
8 months was higher the control group compared to the n-3 PUFA
supplemented group; however, there was no effect on the VEP la-
tency at either of these ages. Furthermore, while there was a sig-
niﬁcant difference in the mean peak latency in the N3 component
of the ﬂash VEP waveform at 50 weeks post-conceptual age (PCA),
the other 14 ﬂash VEP waveforms were not signiﬁcantly different
between the experimental and control groups. In the formula fedinfants, the VEP acuity initially favored the experimental group at 2
months but switched to favor the control group at 4 and 9 months.
Furthermore, between 6 and 8 months and again at 1 year, there
was no signiﬁcant effect observed. In contrast to the VEP test for
visual acuity, the Sweep VEP method shows a better visual acuity at
approximately 4 months and 1 year. With regards to the Teller
acuity method of testing visual acuity, breastfed infants in the n-3
PUFA group had increased visual acuity at 4 months but this dis-
appeared by 6 months, and by at 8 months the control group was
favored. While there were no short term teller acuity outcomes in
the formula group, at 39 months the control group showed
signiﬁcantly better outcomes than the experimental group with or
without the addition of AA. In both the formula and the breastfed
groups, the short term ERG outcomes (Vmax, log rod threshold, log
K, and log s) were not signiﬁcantly affected by n-3 PUFA supple-
ments, but the addition of AA with n-3 PUFA did improve one
parameter (the log K) of ERG tests in formula fed infants. Overall,
the meta-analyses revealed that n-3 PUFA supplements consumed
maternally during gestation and/or lactation or through formula/
direct supplements have no effect on visual acuity. The addition of
AA does not change these results.
4.3. Motor development
The motor development of infants was not affected by n-3 PUFA
supplementation in the categorical data on breastfed (Fig. 5A; SMD
0.098, 95% CI -0.024 to 0.220; seven trials)& Fig. 5B; SMD 0.08, 95%
Fig. 3. N-3 PUFA supplements taken maternally during gestation and/or lactation have no effects on offspring's visual acuity. The combined effects were as follows: Gibson 1997
included results from steady state VEP acuity at 12 and 16 weeks (logMAR); Jensen 2005 combined results from Sweep VEP acuity at 4 months, visual acuity via the TAC method at 4
and 8 months, and VEP amplitudes and latency at 4 and 8 months, Sweep VEP acuity (cy/deg), VEP amplitude and latency, the visual component of the DVMI, and the Bailey Lovie
Acuity results at 5 years of age; Judge 2007 combined the acuities found at 2 and 6 months using the TAC method; DOMInO (a) combined results from the Sweep VEP acuity at 2 and
4 months (logMAR); Malcolm 2003 (b) combined ERG results at 1 week and transient Flash VEP results at birth, 50 and 66 weeks post conceptional age; and ﬁnally, DOMInO (b)
combined VEP latencies at 4 months using 20, 48 and 69 min of arc. Innis 2008 only included visual acuity at 60 days assessed using the TAC method.
Fig. 4. A) N-3 PUFA supplements to formula or directly to the infant have no overall effect on visual acuity. The combined effects were as follows: Auestad 1997 combined the results
obtained from the Beery visual motor index score and the TAC method at 39 months; Birch 2000 combined the results obtained from the HOTV acuity method (logMAR), ERG
results at 6 and 17 weeks and Sweep VEP results (logMAR) at 17 and 52 weeks; Carlson 1996 combined results from the TAC method at 2, 4, 6, 9 and 12 months; and ﬁnally,
Makrides 1999 reported VEP acuity at 34 weeks (logMAR). B) The addition of AA to DHA enriched formula has no overall effect on visual acuity. The combined effect were as follows:
Auestad 1997 included results from the Beery visual-motor index score and using the TAC method at 39 months; Birch 2000 combined HOTV acuity results from the right and left
eye, ERG outputs (Log K, Log Rod Threshold, and Vmax) at 6 and 17 weeks of age, and Sweep VEP outputs at 17 and 52 weeks; Makrides 1999 only included VEP acuity accessed via
the logMAR method.
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the infants' linear motor results (Fig. 5C; Odds Ratio 0.716, 95% CI
0.537 to 0.953; one trial). For example, the general movement's
quality of the infants in the DHA group was lower than in the
control group and exhibited higher accounts of mildly abnormal
movements than the placebo group did at 12 weeks of age, whereas
the control group had greater normal suboptimal general move-
ments, which were classiﬁed as normal. However, the BSID PDI at
30 months and the hand-eye coordination part of the GMDS at 2.5
years favored the experimental group, but conferred no other ad-
vantages (data not shown). The addition of AA prevented the effect
of the DHA supplement on the infant's motor development in the
study summary effect (Fig. 5D; Odds Ratio 0.945, 95% CI 0.701 to
1.274; one trial). The motor development of infants supplemented
with n-3 PUFA in the formula fed group showed no effect, eitherwith (SMD -0.158, 95% CI -0.407 to 0.091; three trials) or without
(SMD 0.055, 95% CI -0.086 to 0.196; eight trials) the addition of AA
(Fig. 6A and B). The n-3 PUFA supplemented group did develop
quicker in some aspects, as they were able to reach an object to
touch, bring a toy to their mouth, sit without support, and walk
alone at a younger age than the control group (data not shown).
4.4. Language development
The language development of infants was not affected by n-3
PUFA supplementation in either breastfed (Fig. 7; SMD -0.076, 95%
CI -0.168 to 0.015; ﬁve trials) or formula fed infants (Fig. 8A; SMD
0.012, 95% CI -0.165 to 0.190; ﬁve trials & Fig. 8B; SMD 0.007, 95% CI
-0.111 to 0.126; two trials). Speciﬁc to formula fed infants, the
experimental group had higher percentile ranks of the MCDI's late
Fig. 5. A) N-3 PUFA supplements taken maternally during gestation and/or lactation have no overall effect on their offspring's motor development. The combined effects were as
follows: Dunstan 2003 included results from the GMDS at 2.5 years (hand eye coordination, locomotor and performance); Gibson 1997 included results from the BSID PDI at 1 and 2
years of age; Jensen 2005 included results from the BSID PDI at 30 months, results from the Gesell gross motor DQ at 30 months and 1 year, results from the DVMI (motor
component and overall effect), the hand movement subset of the K-ABC, the leg coordination subset of the MCDI, and results of the PPT including the dominant and non-dominant
hand at 5 years of age; DOMInO (a) included the age, in months, infants were able to sit without support; DOMInO (b) included the motor standardized score of the BSID at 18
months; and ﬁnally, Tofail 2006 and Van Goor 2009 included results of the BSID PDI at 10 and 18 months, respectively. B) Summery effect shows the addition of AA to n-3 PUFA
supplements taken maternally during gestation and/or lactation has no effect on the outcomes of offspring motor development as was determined through the BSID PDI results at
18 months obtained in Van Goor 2009. C) Summery effect shows that n-3 PUFA supplements taken maternally during gestation and/or lactation signiﬁcantly decrease offspring's’
linear motor development. This summery effect included GM and NNC results at 2 and 12 weeks of age. (P < 0.05) D) Summery effect shows the addition of AA to n-3 PUFA
supplements taken maternally during gestation and/or lactation reversed the effect caused by n-3 PUFA alone on offspring's linear motor development. This summery effect
included GM and NNC results at 2 and 12 weeks of age.
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experimental group was able to articulate the ﬁrst comprehensible
word at a younger age than in the control group and scored higher
on the BSID's language facet at 18 months. In contrast, the control
group obtained higher scores in the MCDI's vocabulary compre-
hension and vocabulary production scales at 14months. In addition
the control group scored higher on the PPVT-III test at 2 and 3.5
years. However, the meta-analyses determined that n-3 PUFA
supplements taken maternally or in formula/directly had no sig-
niﬁcant effect on language development.4.5. Behavior
The behavior of infants was not affected by n-3 PUFAsupplementation in breastfed infants (Fig. 9; SMD 0.070, 95% CI
-0.016 to 0.155; three trials). Formula fed infants supplemented
with n-3 PUFA likewise showed no signiﬁcant effect (Fig. 10A; SMD
0.020, 95% CI -0.061 to 0.1; three trials); however, the addition of
AA to the n-3 PUFA supplemented, formula fed infants, had a
negative summary effect on behavior (Fig. 10B; SMD -0.116, 95% CI
-0.194 to 0.039; one trial) with the control group smiling and
laughing more at 1 year of age.4.6. Cognition
The cognition of infants was largely unaffected by n-3 PUFA
supplementation in both breastfed (Fig. 11; SMD -0.001, 95% CI
-0.070 to 0.069; eight trials) and formula fed infants (Fig. 12A;
Fig. 6. A) n-3 PUFA supplements to formula or directly to the infant have no effect on motor development. Combined effects were as follows: Agostoni 2009 combined the age that
infants were able to bring a toy to their mouth, crawl, reach an object to touch, sit without support, stand and walk alone; DIAMOND combined BSID Motor and PDI at 18 months;
Lucas 1999 combined BSID PDI at 18 months with the ﬁne and gross motor function of the KPST; Makrides 1999 combined the BSID PDI at 1 and 2 years; and ﬁnally, D'Vaz 2012
combined the ﬁne and gross motor standardized scores with the motor composite score at 18 months. The single results obtained from Agostoni 1995, Bouwstra 2003 and Auestad
1997 were from the Brunet- Lezine DQ at 4 month and 2 years, BSID PDI at 18 months and BSID PDI at 1 year, respectively. B) The addition of AA to n-3 PUFA in formula or directly to
the infant has no effect on motor development. Combined effects were as follows: Auestad 1997 shows results from the BSID PDI at 1 year; Auestad 2001 included BSID PDI at 6
months and 1 year; and Makrides 1999 included BSID PDI at 1 and 2 years. .
Fig. 7. N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on the language development in offspring. Combined effects were as follows:
Dunstan 2003 included the mean length of phrases using the CBCL, the speech and hearing portion of the GMDS, and the results from the PPVT and vocabulary centile score at 2.5
years; Jensen 2005 included results from the CLAMS DQ at 30 months and 1 year; DOMInO (a) included results from the MCDI (late gestures, phrases understood, vocabulary
comprehension) at 1 year and vocabulary production and length of the longest sentence at 2 years. Dunstan 2003 reported a vocabulary centile score at 2.5 years; Jensen 2005
reported a vocabulary subset of the WPPSI-R at 5 years and DOMInO (b) reported the BSID language standardized score at 18 months.
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95% CI -0.137 to 0.214; ﬁve trials. Fig. 12C; Odds Ratio 1.086, 95% CI
0.782 to 1.507; one trial). Although 6 tests were unchanged in both
the breastfed and formula fed infants during all time points (WJ
test, Stroop test, WPPSI, Fagan test, Cat DQ and GMDS), there were
a few tests that favored n-3 PUFA supplementation for both
breastfed and formula fed infants. In breastfed infants, the
experimental groups scored higher on the 2 step-cloth intentional
solutions at 9 months, received higher scores on the sustained
attention portion of the Leiter test at 5 years of age and scored
higher on the K-ABC mental processing at 4 years of age (indi-
vidual data not shown). Similarly, for formula fed infants, the
experimental group obtained higher score on the 2 step-intention
score at 9 months, higher scores of sustained attention at 9
months, as well as on the BSID-cognitive standardized score at 18
months and scored lower on the MFFT at 6 years of age whichindicates a more efﬁcient processing (individual data not shown).
However, these results appeared randomly throughout time as
they were not seen at all ages even when measured in the same
cohort. For example, the formula fed infants did not show any
signiﬁcant differences in the 2 step-problem solving test at 1 year,
in the sustained attention scores at 4 or 6 months, or the BSID
scores at 6 months, 1 year, or 2 years. Overall, the meta-analyses
show no signiﬁcant differences in either the breastfed or for-
mula fed/directly supplemented infants.
4.7. Growth
The growth of infants was not affected by n-3 PUFA supple-
mentation in either breastfed (Fig. 13A; SMD 0.038, 95% CI -0.019
to 0.094; 15 trials. Fig. 13B; SMD 0.028, 95% CI -0.023 to 0.079; 15
trials. Fig. 13C; SMD 0.015, 95% CI -0.248 to 0.279; one trial. Fig. 15;
Fig. 8. A) n-3 PUFA supplements to formula or directly to the infant have no effect on language development. Combine effects were as follows: Auestad 1997 included results from
the PPVT-R: receptive and expressive vocabulary at 39 months and results from the MCDI (early gestures, late gestures, phrases understood, vocabulary comprehension and
production) at 14 months; DIAMOND included results from the PPVT at 2 and 3.5 years and the BSID: language subset at 18 months; D'Vaz 2012 included results from the BSID
(Language composite score and standardized expressive and receptive language) and the MCDI (Early gestures, late gestures, phrases understood total gestures, words spoken and
words understood) at 18 months and 1 year. . Lucas 1999 reported the language subscale of the KPST at 9 months. B) The addition of AA to n-3 PUFA in formula or directly to the
infant has no effect on language development. Combined effects were as follows: Auestad 2001 included results from the MCDI (vocabulary comprehension at 9 and 14 months and
vocabulary expression at 14 months); Auestad 1997 included results from the PPVT-R: expressive and receptive vocabulary at 39 months, and results from the MCDI (early gestures,
late gestures, phrases understood, vocabulary comprehension and vocabulary production) at 14 months.
Fig. 9. n-3 PUFA supplements taken maternally during gestation and/or lactation have no effects on offspring behavior. Combined effects were as follows: DOMInO (a) included
results from the SDQ (conduct score, emotional score, hyperactivity score, peer problems score, prosocial score and total difﬁculties) at 7.5 years; Dunstan 2003 included results
from the CBCL (internalizing, externalizing total problem behavior scales) and the personal social score of the GMDS at 1.5e5 years; DOMInO (b) included results from the BSID
(adaptive behavior standardized score and social emotional standardized score at 18 months.
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95% CI -0.025 to 0.083; 10 trials. Fig. 19A; SMD -0.13, 95% CI -0.293
to 0.033; three trials. Fig. 19B; SMD 0.031, 95% CI -0.157 to 0.220;
three trials) or formula fed infants (Fig. 14A; SMD -0.060, 95% CI
-0.138 to 0.018; six trials. Fig. 14B; SMD -0.068, 95% CI -0.146 to
0.010; six trials. Fig. 14C; SMD 0.000, 95% CI -0.229 to 0.229; two
trials. Fig. 14D; SMD -0.065, 95% CI -0.294 to 0.164; two trials.
Fig. 14E; SMD 0.027, 95% CI -0.100 to 0.154; one trial. Fig. 16A; SMD
-0.049, 95% CI -0.125 to 0.028; six trials. Fig. 16B; SMD -0.016, 95%
CI -0.214 to 0.247; two trials. Fig. 16D; SMD -0.032, 95% CI -0.200 to
0.136; one trial. Fig. 18A; SMD -0.031, 95% CI -0.112 to 0.049; six
trials. Fig. 18B; SMD 0.079, 95% CI -0.150 to 0.308; two trials.
Fig. 18C; SMD -0.026, 95% CI -0.296 to 0.243; two trials. Fig. 20A;
SMD -0.065, 95% CI -0.138 to 0.007; three trials. Fig. 20B; SMD
-0.086, 95% CI -0.214 to 0.041; one trial). However, the summery
effect shows that the addition of AA to n-3 PUFA supplements in
formula or directly to the infant has a negative effect on head
circumference, z-scores (Fig. 18D; SMD -0.194, 95% CI -0.363to 0.026; one trial) and a positive effect on height z-scores
(Fig. 16C; SMD 0.103, 95% CI 0.001 to 0.205; two trials). In all cases,
results were combined if measurements were taken over time. In
both breastfed and formula fed infants, the control group weighed
more at 21e24 months of age with a signiﬁcant difference in
weight at 2.5 years for breastfed infants, but the weight difference
disappeared by the age of 6 and 7 years old (individual data not
shown). With regards to height, in breastfed infants the control
group was signiﬁcantly taller than the experimental group at 1
year of age; however, this difference disappeared as the infants
aged whereas in formula fed infants there was no effect. Inter-
estingly, n-3 PUFA supplementation had opposite effects on head
circumference when it was delivered through breastmilk verses
formula. In breastfed infants, the experimental group had larger
heads in infants at 9 months and 2 years of age and in formula
infants at 3 months, the control group had larger heads. There
were additional differential effects of n-3 PUFA whether it was
delivered in breastmilk verses formula. For example, in breastfed
Fig. 10. A) N-3 PUFA supplements to formula or directly to the infant have no signiﬁcant effect on behavior. Combined effects were as follows: DIAMOND included results from the
BBCS-R (direction, quantity, school readiness composite, self and social awareness, textures and materials, time and sequence) at 2.5 years and the behavior rating scale of the BSID
at 18 months; D'Vaz 2012 included results from the BSID (composite adaptive behavior, composite social emotional score, and standard social emotional score) at 18 months as well
as the CBCL (externalizing, internalizing and total behaviors) at 18 months. Lucas 1999 reported on the personal-social subscale of the KPST at 9 months. B) Summery effect shows
the addition of AA to n-3 PUFA supplements in formula or taken directly has a negative effect on behavior. The combined effects were as follows: Auestad 2001 included results from
the IBQ (Soothability, activity level, distress to limitations, distress to novel stimuli, duration of orientation, and smiling and laughter) at 6 months and 1 year. P < 0.05.
Fig. 11. N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring cognition. Combined effects were as follows: DOMInO (a) included
results from the Stroop test (higher-order cognitive function) at 7 years and the Woodcock Johnson test of cognitive abilities (information processing subtest) at 7.5 years and a 2
step problem at 9 months,; Dunstan 2003 included results from the GMDS (general quotient score and practical reasoning) at >30 months; Helland 2001 included results from the
Fagan test at 6 and 9 months; Jensen 2005 included results from the BSID MDI at 30 months, and the CAT DQ at 30 months and 1 year, results from the WPPSI-R (animal pegs, block
design and information subset) and the sustained attention protein of the Leiter test at 5 years; and Judge 2007 included results from the 2 step test at 9 months and the Fagan test
(No. of looks, risk score, scaled novelty score, and time spent looking) at 9 months. DOMInO (b) used the BSID cognitive standardized score at 18 months, and Tofail 2006 and Van
Goor 2009 used the BSID MDI at 10 and 18 months, respectively.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e5444infants, n-3 PUFA supplementation resulted in higher BMI at birth
and 2.5 years, higher fat mass at 1 year, higher waist circumfer-
ence, an increase in skinfold thicknesses, higher body fat as a
percentage at 2.5 years and higher triceps skinfold thickness at 6
years. In contrast, n-3 PUFA supplementation in formula resulted
in infants showing decreased subscapular skinfold thickness at 6
weeks and 3 months as well as decreased triceps skinfold thick-
ness at 3 months. However, the triceps skinfold thickness is
increased at 9 months and 1 year, the subscapular skinfold thick-
ness is increased at 1 year, and the mid upper arc circumference
(MUAC) is increased at 1 year in the n-3 PUFA supplemented
group. Although Figs. 16C and 18D shows signiﬁcance, the height
and head circumference in the formula fed group was not affected;
therefore, the overall results from our study analysis showed no
effect on the growth parameter caused by n-3 PUFA supplements
with or without the addition of AA.4.8. Cardiovascular health
The cardiovascular health of infants, including the DBP and MAP
was not affected by n-3 PUFA supplementation in either breastfed
(Fig. 21; SMD -0.089, 95% CI -0.224 to 0.047; one trial) or formula
fed infants (Fig. 22; SMD 0.083, 95% CI -0.076 to 0.243; one trial).
However, it was found that the breastfed infants had a signiﬁcantly
higher SBP andMAP in the DHA group than in the control group at 7
years of age P< 0.001 (see combined results fromDOMInO (a)). This
suggests that maternal DHA supplements may have a negative ef-
fect on their offspring's cardiovascular health in the long-term.
4.9. Immunity
Unlike the majority of meta-analyses outcomes measured
showing no effect of n-3 PUFA supplementation, the immune status
Fig. 12. A) n-3 PUFA supplements to formula or directly to the infant have no signiﬁcant effect on cognition. Combined effects were as follows: Birch 2000 included results from the
WPPSI-R (full scale IQ, performance and verbal IQ) at 4 months; DIAMOND included the peak look and sustained attention and 4, 6, 9 and 12 months and results from the BSID test
(cognitive standardized score and MDI) at 18 months; Birch 2005 included the intention score of the 2 step problem at 9 months (including infants that were weaned at 4e6, 6 and
9 months); Makrides 1999 included the BSID MDI at 1 and 2 years; D'Vaz 2012 included results from the BSID test (cognitive composite score and cognitive standardized score) at 18
months; and Willatts 1998 included both the intention score and solutions of a 2 step problem at 1 year and 9 months, respectively, and results from the WPPSI-R and the MFFT at 6
years. Auestad 1997 reported on the Standord-Binet IQ at 39 months and the BSID MDI at 1 year; Bouwstra 2003 reported on the BSID MDI at 8 months; and Lucas 1999 reported on
the BSID MDI at 18 months. . B) The addition of AA to n-3 PUFA in formula or directly to the infant has no effect on cognition. Combined effects were as follows: Auestad 2001
included results from the BSID MDI, and the Fagan test (look duration during familiarization and testing and novelty preference) at 6 and 9 months; Birch 2000 included results
from the WPPSI-R (full scale IQ, performance IQ and verbal IQ) at 4 years; and Makrides 1999 included the BSID MDI at 1 and 2 years. Auestad 1997 reported on the Stanford-Binet
IQ at 39 months and the BSID MDI at 1 year. C) Summery effect shows that n-3 PUFA supplements to formula or directly to the infant have no effects on the linear outcomes of
cognition using the neonatal neurological classiﬁcation system (complex minded, normal, and simple minded) at 9 months.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e54 45of infants showed signiﬁcant changes in both breastfed (Fig. 23A;
SMD -0.207, 95% CI -0.355 to 0.059; 1 trial & Fig. 23B; Odds Ratio
1.139, 95% CI 1.083 to 1.198; ﬁve trials) and formula fed infants
(Fig. 24A; SMD -0.220, 95% CI -0.375 to0.065; one trial), but not in
the formula fed, linear outcomes (Fig. 24B; Odds Ratio 1.053, 95% CI
0.911 to 1.217; one trial). In the infants born to mothers supple-
menting their diets with n-3 PUFA, infants in the control group had
signiﬁcantly more CD8þ T cells, CD4þIFN-g T cells and CD8þIFN-g
T cells whereas CD45RO þ CD8þ T cells (memory/activated sup-
pressor cells), CD45RAþ CD8þ Tcells (naïve T suppressor cells) and
CD45RA þ CD4þ T cells (naïve helper cells) were more abundant in
the experimental group (individual data not shown). The infants
fed formula showed similar results whereby the experimental
group hadmore CD8þT suppressor cells and CD45RAþ CD8þTcells
at 2 weeks, as well as higher CD8þCD28þ T cells at 2 weeks, higher
CD4þCD28þ T cells, CD3þCD44 T cells, and CD3þT cells at 6 weeks
and lower CD20þ B cells and TNFawith PHA at 6 weeks (individual
data not shown). We deﬁned any anti-inﬂammatory responses to
be a “negative” result, as shown in Table S17A and Table S18A.
When looking at the linear outcomes, we found that breastfedinfant control group exhibited higher counts of IFN-g positive cord
blood mononuclear cells to ovalbumin (OVA). Furthermore, the SPT
reactions to egg, and egg sensitization, food allergy, IgE to eczema,
any positive SPT result, eczemawith sensitization, and sensitization
with/without allergic disease at one year was higher in the control
group consistent with the control group also having more IgE
associated disease at 2 years. These results were not seen in the
formula fed group as no differences were seen in the SPT to house
dust mites (HDM), cat, egg, or peanut at 1 year. Furthermore in the
breastfed infants, the control group had a more severe SCORAD
index score at 1 year, which ranks the severity of atopic eczema and
hadmore incidences of colds than the DHA group at 1month. Taken
together, these studies reveal that n-3 PUFA supplements promote
anti-inﬂammatory responses.
5. Discussion
The overall outcome of this meta-analysis indicates that sup-
plementing infants with long chain n-3 PUFA largely have no effect
on visual acuity, growth or language development. Aspects of
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Bergmann 2007 Combined -0.131 0.086 0.007 -0.300 0.037 -1.527 0.127
DOMInO (a) Combined 0.206 0.101 0.010 0.009 0.404 2.045 0.041
DOMInO (b) Weight at birth (kg) 0.119 0.041 0.002 0.039 0.199 2.919 0.004
Dunstan 2003 Combined -0.000 0.172 0.030 -0.338 0.338 -0.000 1.000
Furuhjelm 2009 Weight at birth (kg) -0.179 0.186 0.035 -0.545 0.186 -0.962 0.336
Granot 2011 Weight at birth (kg) 0.066 0.258 0.067 -0.440 0.572 0.257 0.798
Hauner 2012 Combined 0.102 0.075 0.006 -0.045 0.249 1.364 0.173
Helland 2001 Combined 0.060 0.075 0.006 -0.088 0.208 0.801 0.423
Innis 2008 Weight at birth (kg) -0.204 0.173 0.030 -0.542 0.134 -1.182 0.237
Jensen 2005 Weight at 5 yr (kg) 0.113 0.183 0.034 -0.247 0.473 0.616 0.538
Judge 2007 Combined 0.394 0.263 0.069 -0.122 0.909 1.497 0.134
Malcolm 2003 Combined -0.106 0.154 0.024 -0.407 0.195 -0.689 0.491
Stein 2010 Combined 0.003 0.035 0.001 -0.066 0.071 0.076 0.939
Tofail 2006 Weight at birth (kg) 0.000 0.127 0.016 -0.248 0.248 0.000 1.000
Van Goor 2009 Combined -0.006 0.133 0.018 -0.267 0.254 -0.049 0.961
0.038 0.029 0.001 -0.019 0.094 1.300 0.193
-1.00 -0.50 0.00 0.50 1.00
Favours Control Favours Experimental
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Bergmann 2007 Combined -0.131 0.086 0.007 -0.300 0.037 -1.527 0.127
DOMInO (a) Combined 0.069 0.101 0.010 -0.129 0.266 0.679 0.497
DOMInO (b) Weight at birth (kg) 0.119 0.041 0.002 0.039 0.199 2.919 0.004
Dunstan 2003 Combined 0.014 0.173 0.030 -0.325 0.353 0.079 0.937
Furuhjelm 2009 Weight at birth (kg) -0.179 0.186 0.035 -0.545 0.186 -0.962 0.336
Granot 2011 Weight at birth (kg) 0.066 0.258 0.067 -0.440 0.572 0.257 0.798
Hauner 2012 Combined 0.102 0.075 0.006 -0.045 0.249 1.364 0.173
Helland 2001 Combined 0.060 0.075 0.006 -0.088 0.208 0.801 0.423
Innis 2008 Weight at birth (kg) -0.204 0.173 0.030 -0.542 0.134 -1.182 0.237
Jensen 2005 Weight at 5 yr (kg) -0.113 0.183 0.034 -0.473 0.247 -0.616 0.538
Judge 2007 Combined 0.394 0.263 0.069 -0.122 0.909 1.497 0.134
Malcolm 2003 Combined -0.106 0.154 0.024 -0.407 0.195 -0.689 0.491
Stein 2010 Combined 0.003 0.035 0.001 -0.066 0.071 0.076 0.939
Tofail 2006 Weight at birth (kg) 0.000 0.127 0.016 -0.248 0.248 0.000 1.000
Van Goor 2009 Combined -0.006 0.133 0.018 -0.267 0.254 -0.049 0.961
0.028 0.026 0.001 -0.023 0.079 1.063 0.288
-1.00 -0.50 0.00 0.50 1.00
Favours Control Favours Experimental
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Van Goor 2009 Combined 0.015 0.134 0.018 -0.248 0.279 0.115 0.909
0.015 0.134 0.018 -0.248 0.279 0.115 0.909
-0.50 -0.25 0.00 0.25 0.50




Fig. 13. A) N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring weight where weight in children aged 2e5 is considered beneﬁcial.
B) N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring weight where weight in children aged 2e5 is considered detrimental. C)
Summery effect shows that the addition of AA to the n-3 PUFA supplements taken maternally during gestation and/or lactation had no effect on offspring weight. Results were
combined if weight measurements were taken over a time period.
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breastfed individuals. Likewise, negative behavior effects were seen
in formula fed infants being supplemented with n-3 PUFA and AA.
Curiously, n-3 PUFA supplementation has targeted effects on car-
diovascular and immunity depending on whether the infant was
breastfed or formula fed suggesting that background nutrition may
be central to the interpretation of the effectiveness of n-3 PUFA.
N-3 PUFA supplementation has often been associated with
growth parameters. While there was no difference in the overall
growth parameters when pooled by study, it was found that n-3
PUFA supplements signiﬁcantly alter growth parameters when
pooled by age (data not shown). Larger additional growth param-
eters were deemed detrimental over the age of ﬁve due to the
prevalence of childhood obesity. The data shows that children in
the n-3 PUFA supplemented, breastfed group have larger growth
parameters over the age of ﬁve. During adiposity, children sup-
plemented with n-3 PUFA through breastmilk also have larger
growth parameters. There was no effect on the additional growthparameters under the age of two. Despite the values being larger in
the n-3 PUFA supplemented children, they were still within the
healthy range.
While n-3 PUFA supplementation has little effect on cardio-
vascular function in infants overall, n-3 PUFA supplementation
does have the opposite effect on systolic blood pressure in formula
compared to breastfed infants. While both groups fell within a
normal range for their ages, n-3 PUFA supplementation did elevate
blood pressure in breastfed infants, suggesting supplementation
actually has an undesired effect. This is because elevated blood
pressure detected in early childhood is predictive of high blood
pressure in late adolescence [101] which results in heart failure
later in life [102].
N-3 PUFA has long been associated with immune modulation.
N-3 PUFA supplementation decreases IFN-g production and in-
creases naïve cells suggesting n-3 PUFA is associated with the
reduction of pro-inﬂammatory responses and the induction of anti-
inﬂammatory responses. Considering that developing infants need
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
DIAMOND Combined 0.027 0.065 0.004 -0.100 0.154 0.421 0.674
0.027 0.065 0.004 -0.100 0.154 0.421 0.674
-0.25 -0.13 0.00 0.13 0.25
Favours Control Favours Experimental
E.
Fig. 14. A) N-3 PUFA supplements to formula or directly to the infant have no effects on child weight where weight in children aged 2e5 is considered beneﬁcial. B) N-3 PUFA
supplements to formula or directly to the infant have no effects on child weight where weight in children aged 2e5 is considered detrimental. C) The addition of AA to the n-3 PUFA
in formula or directly to the infant had no effect on child weight where weight in children aged 2e5 is considered beneﬁcial. D)The addition of AA to the n-3 PUFA in formula or
directly to the infant had no effect on child weight where weight in children aged 2e5 is considered detrimental. E) Summery effect shows that n-3 PUFA supplements to formula or
directly to the infant have no effect on weight, z-scores. Results were combined if weight measurements were taken over time.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e54 47to undergo priming of their immune responses during the ﬁrst few
years of life, suppressing the normal development of immunity
may have consequences considering a robust immune response is
required to ﬁght off infectious disease. In support of this, rodents
fed n-3 PUFA have been shown to be more susceptible to several
pathogens suffering greater morbidity and mortality [103,104]. On
the other hand, breastfed infants exposed to n-3 PUFA, and notformula fed infants, do have less IgE-associated disease at 2 years of
age. Decreasing allergies is of clinical importance; however, un-
derstanding the potential consequences of altering the balance of
immune cells in a developing infant needs to be further
investigated.
Previous meta-analyses, following the Cochrane guidelines,
analyzed the effects of n-3 PUFA on health and development of
Fig. 15. N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring height. Results were combined if height measurements were taken
over time.
Fig. 16. A) N-3 PUFA supplements to formula or directly to the infant have no effects on child height. B) The addition of AA to the n-3 PUFA in formula or directly to the infant has no
effect on child height. C) Summery effect shows that N-3 PUFA supplements to formula or directly to the infant has a positive effect on height, z-scores. D). Summery effect shows
that the addition of AA to n-3 PUFA supplements in formula or directly to the infant has no effect on the height, z-scores. Results were combined if height was measured over time.
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Fig. 17. N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring head circumference. Head circumferences were combined if mea-
surements were taken over time.
Fig. 18. A) N-3 PUFA supplements to formula or directly to the infant have no effects on child head circumference. B) The addition of AA to n-3 PUFA supplements in formula or
directly to the infant has no effect on child head circumference. C) N-3 PUFA supplements to formula or directly to the infant have no effects on head circumference, z-scores. D)
Summery effect shows that the addition of AA to n-3 PUFA supplements in formula or directly to the infant has a negative effect on head circumference, z-scores. Results were
combined if measurements were taken over time.
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Fig. 19. A) N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring's addition growth parameters where the additional growth
parameters in children aged 2e5 is considered beneﬁcial. B) N-3 PUFA supplements taken maternally during gestation and/or lactation have no effect on offspring's additional
growth parameters where the additional growth parameters in children aged 2e5 is considered detrimental. Combined effects were as follows: Bergman 2007 included BMI
measurements at birth, 1, 3 and 21 months, as well as measurements of abdominal girth, BMI, hip size, subscapular SFT, sum of SFT, and Triceps SFT at 6 years; Hauner 2012 included
measurements of BMI, fat mass, subscapular triceps SFT, sum of SFT, and trunk to total SFT at birth, 6 weeks, 4 months and 1 year; DOMInO (a) included measurements of BMI at 2, 4,
9, and 18 months, and lean body mass, sum of SFT, triceps SFT and waist circumference at 18 months.
Fig. 20. A) N-3 PUFA supplements to formula or directly to the infant have no effect on addition growth parameters. Combined effects were as follows: Decsi 1995 included
measurements of head circumference gain, height gain, and weight as a percentage of birth weight at 4 months; Lucas 1999 included measurements of the mid-upper arm
circumference, and the sum of SFT at 6, 9 and 18 months; Morris 2000 included measurements of the mid-arm circumference, the subscapular SFT, and the triceps SFT at birth, 6
weeks, 3 months, 6 months, and 1 year. B) Summery effect shows that N-3 PUFA supplements to formula or directly to the infant have no effect on the additional growth pa-
rameters, z-score. Combined results were as follows: DIAMOND included measurements of weight-for-length at 4, 6, 9, 12, and 18 months.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e5450infants [14,15]. While these meta-analyses also concluded that n-3
PUFA supplementation has little effect on infant development, the
Cochrane protocol does result in selection bias due to their selec-
tion inclusion approach which can alter the outcome of the meta-
analysis [22,105]. Here, we used the Comprehensive Meta-
analysis V3 program enabling the testing of multiple time points,
outcomes and intervention groups whilst avoiding multiplicity
[106]. However, this study still has some unavoidable limitations.
Differences in background diets may have confounding effects on
the inﬂuence of the intervention as these studies spanned a wide
array of countries with different cultures and socioeconomicconditions. Another problem could be that there were no consis-
tencies between the source, dose or duration of n-3 PUFA supple-
mentation. In addition, varying test methods were used to compute
similar outcomes. For example each study used different versions of
the BSID. Furthermore, the testing methods may not be fully reli-
able. For example, it has been suggested the Bayley Scales (BSID) do
not provide an adequate measure of infant cognitive ability, but are
instead appropriate for measuring incidence of developmental
delay, as has been demonstrated [89]. Likewise, the Gesell Devel-
opmental DQ is no longer considered an acceptable standard of
psychometrics. While we were able to address the issue of nested
Fig. 21. Summery effect shows that N-3 PUFA supplements taken maternally during gestation and/or lactation has no effect on cardiovascular health. Combined effects were as
follows: DOMInO (a) included DBP, MAP and SBP at 7 years DBP, SDSNNi, HR, MAP, pNN, PWV, RMSSD, RR, SBP and SDANN at 2.5 years.
Fig. 22. Summery effect shows that N-3 PUFA supplements to formula or directly to the infant have no effect on cardiovascular health. Combined effects were as follows: Bouwstra
2003 included the DBP, the SBP and the HR at 9 years.
Fig. 23. A) Summery effect shows that n-3 PUFA supplements taken maternally during gestation and/or lactation have targeted changes to offspring's immunity. P < 0.05.B) N-3
PUFA supplements taken maternally during gestation signiﬁcantly affect the linear immune outcomes. P < 0.05.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e54 51multiplicity, our study still contains multiplicity from where we
separated data into different categories (such as the DHA þ AA).
This could increase the type 1 error associated with these studies.
Additionally, some analyses only contain one study and thus we
used the analysis to present the overall summery effect from that
paper. Therefore, no deﬁnitive conclusions can be drawn on these
categories, thus, there needs to be more independent studies done
on DHA, as well as DHA þ AA for a more precise meta-analysis.
Some studies had to be excluded because the data was presented
in a way that was not feasible and we were unable to receive theraw data from the authors. In addition, the quality of the included
studies ranged in terms of bias. With regards to language devel-
opment, a possible bias in the MCDI results is that it was reported
that 92.9% of the participants in the n-3 PUFA group were able to
guess their infant's group allocation and because the MCDI is a
parent reporting test, this could have improved the parent's
perception of their child's abilities [60]. In the studies, raw datawas
often transformed or adjusted for confounding variables before it
was analyzed. While these adjustments likely give a more accurate
depiction of the outcome beingmeasured, not all papers performed
Fig. 24. A) Summery effect shows that n-3 PUFA supplements to formula or directly to the infant signiﬁcantly decrease inﬂammatory responses in infants. B) Summery effect shows
that n-3 PUFA supplements to formula or directly to the infant have no linear effects on immunity. P < 0.05.
C. Quin et al. / Journal of Nutrition & Intermediary Metabolism 5 (2016) 34e5452the same adjustments. As such, we used the raw data and
acknowledge that some of our outcomes reported may differ
slightly from the original article.
In conclusion, n-3 PUFA supplementation in infants delivered
either maternally or in formula, does not improve visual acuity,
growth or language development. However, some aspects of motor,
cardiovascular health, behavior and immunity are differentially
affected by n-3 PUFA supplementationwith the more desired effect
occurring often in breastfed infants compared to formula fed in-
fants. Overall, the evidence does not support the continued sup-
plementation of infant formula although more studies are required
to understand the effects of maternal n-3 PUFA supplementation on
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